Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
Immunoconjugates
Known as:
Icon
, Immunoconjugate
, Immunoconjugates [Chemical/Ingredient]
Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or…
Expand
National Institutes of Health
Create Alert
Related topics
Related topics
40 relations
Narrower (30)
AGS67E
AMG 595
ANG4043
D2C7-(scdsFv)-PE38KDEL
Expand
Broader (2)
Antibodies
Immunologic Factors
BRENTUXIMAB
Bispecific CD19-directed CD3-directed T Cell Engager [EPC]
Immunotherapy
Immunotoxicity
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.
A. Advani
,
B. Coiffier
,
+17 authors
L. Fayad
Journal of clinical oncology : official journal…
2010
Corpus ID: 23276881
PURPOSE Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody…
Expand
Highly Cited
2008
Highly Cited
2008
Contribution of linker stability to the activities of anticancer immunoconjugates.
S. Alley
,
D. Benjamin
,
+4 authors
P. Senter
Bioconjugate chemistry
2008
Corpus ID: 31132425
The linker component of antibody-drug conjugates (ADC) is a key feature in developing optimized therapeutic agents that are…
Expand
Review
2005
Review
2005
Arming antibodies: prospects and challenges for immunoconjugates
A. Wu
,
P. Senter
Nature Biotechnology
2005
Corpus ID: 27226728
Immunoconjugates—monoclonal antibodies (mAbs) coupled to highly toxic agents, including radioisotopes and toxic drugs…
Expand
Highly Cited
2005
Highly Cited
2005
Structural characterization of the maytansinoid–monoclonal antibody immunoconjugate, huN901–DM1, by mass spectrometry
L. Wang
,
G. Amphlett
,
W. Blättler
,
J. Lambert
,
W. Zhang
Protein science : a publication of the Protein…
2005
Corpus ID: 46441527
Immunoconjugates are being explored as novel cancer therapies with the promise of target‐specific drug delivery. The…
Expand
Highly Cited
2005
Highly Cited
2005
In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
R. Sanderson
,
Michelle A Hering
,
+5 authors
A. Wahl
Clinical cancer research : an official journal of…
2005
Corpus ID: 24389123
Effective antibody-drug conjugates (ADC) combine high drug-linker stability in circulation and efficient intratumoral release of…
Expand
Highly Cited
2004
Highly Cited
2004
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.
J. Dijoseph
,
Douglas C Armellino
,
+12 authors
N. Damle
Blood
2004
Corpus ID: 17543492
Antibody-targeted chemotherapy with gemtuzumab ozogamicin (CMA-676, a CD33-targeted immunoconjugate of N-acetyl-gamma…
Expand
Highly Cited
2002
Highly Cited
2002
Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer…
G. Dubowchik
,
R. Firestone
,
+6 authors
P. Trail
Bioconjugate chemistry
2002
Corpus ID: 29192189
The anticancer drug doxorubicin (DOX) has been linked to chimeric BR96, an internalizing monoclonal antibody that binds to a…
Expand
Highly Cited
1999
Highly Cited
1999
Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate.
E. Sievers
,
F. Appelbaum
,
+6 authors
I. Bernstein
Blood
1999
Corpus ID: 40525602
Leukemic blast cells express the CD33 antigen in most patients with acute myeloid leukemia (AML), but this antigen is not…
Expand
Highly Cited
1993
Highly Cited
1993
Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates.
P. Trail
,
D. Willner
,
+6 authors
K. Hellstroem
Science
1993
Corpus ID: 13092725
Immunoconjugates (BR96-DOX) were prepared between chimeric monoclonal antibody BR96 and the anticancer drug doxorubicin. The…
Expand
Highly Cited
1992
Highly Cited
1992
Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
R. Chari
,
B. Martell
,
+5 authors
V. Goldmacher
Cancer research
1992
Corpus ID: 34036508
The potential of immunoconjugates of cytotoxic drugs for the treatment of cancer has not yet been realized owing to the…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE